...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy: International Journal of Experimental and Clinical Chemotherapy >A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
【24h】

A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.

机译：头孢吡肟与头孢他啶作为中性粒细胞减少症患者高热发作的经验疗法的比较研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

An open-label, randomized comparative study was conducted to evaluate the efficacy and safety of cefepime (2.0 g q. 8 h) and ceftazidime (2.0 g q. 8 h) in the empiric therapy of febrile neutropenic patients. A total of 45 eligible febrile episodes were randomized (1:1) to be treated with the study regimen. Nineteen febrile episodes treated with cefepime and 22 febrile episodes treated with ceftazidime were evaluable for efficacy. The two groups were comparable in terms of age, sex, height, weight, underlying neoplasm, number of pretherapy neutrophil, duration of neutropenia and types of infections. The overall therapeutic success rate of the cefepime group (53%) was comparable to the ceftazidime group (50%). It did not differ significantly (95% confidence interval: -0.28 to 0. 34, p = 0.85). Eighty-eight percent of pathogens in each group were bacteriologically eradicated. The safety profile was similar in both groups. No patients in either group discontinued the therapy because of adverse events. None (0%) of the cefepime patients and 2 (9%) of the ceftazidime patients died of infection. The results of this study suggest that cefepime is an effective and safe agent in the empiric therapy of febrile episodes in neutropenic patients.
机译：进行了一项开放标签的随机比较研究，以评估头孢吡肟（2.0 g q。8 h）和头孢他啶（2.0 g q。8 h）在发热性中性粒细胞减少症患者的经验疗法中的疗效和安全性。将总共​​45例符合条件的高热发作随机（1：1）进行研究方案治疗。头孢吡肟治疗19例高热发作和头孢他啶治疗22例高热发作可评估疗效。两组在年龄，性别，身高，体重，基础肿瘤，治疗前中性粒细胞数量，中性粒细胞减少的持续时间和感染类型方面具有可比性。头孢吡肟组的总体治疗成功率（53％）与头孢他啶组（50％）相当。它没有显着差异（95％置信区间：-0.28至0。34，p = 0.85）。每组中有88％的病原体被细菌根除。两组的安全性相似。两组中没有患者因不良事件而中断治疗。头孢吡肟患者（0％）和头孢他啶患者中有2（9％）因感染而死亡。这项研究的结果表明，头孢吡肟是经验性治疗中性粒细胞减少症患者高热发作的有效且安全的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号